Rui Ping Dong

OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY.

OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY.

OptMed, Inc. is a clinical-stage medical device company, which engages in the development and commercialization of surgical adhesives for the treatment of patients with external and internal wounds. The firm offers products under the brands of BondEase Topical Skin Adhesive and TearRepair Liquid Skin Protectant. Its proprietary technology platform is based on a chemistry called methylidene malonate (MM212), a biocompatible polymer originally designed for drug delivery which has been tested for biocompatibility and adhesive properties in topical and internal applications. The company was founded by Alain Klapholz in 2007 and is headquartered in New York, NY.